Ocular Inflammation Associated with Polymyalgia Rheumatica without Concomitant Giant-Cell Arteritis: A Report of Three Cases

Arai, Takahiro; Tanaka, Rie; Kaburaki, Toshikatsu

doi:10.1080/09273948.2017.1278776

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case series and disease cohorts of patients with PMR reveal a high incidence of glucocorticoid-related adverse events including osteoporosis, fracture, diabetes, weight gain, hypertension, diabetes, myocardial infarction and stroke (32)(33)(34)(35)(36)(37). This in itself is important for making treatment decisions regarding adjustment of GC therapy, or commencement steroid sparing therapy, in PMR.…”

Section: Glucocorticoid-related Adverse Events In Polymyalgia Rheumaticamentioning

confidence: 99%

Comorbidity in polymyalgia rheumatica

Chatzigeorgiou

McDermott

2018

Reumatismo

View full text Add to dashboard Cite

Polymyalgia rheumatica (PMR) is the commonest inflammatory rheumatic disease affecting older people. The current mainstay of treatment is long-term oral glucocorticoid therapy. Management of these patients in clinical practice is often complicated by the presence of comorbidity. Comorbidity might be due to shared risk factors such as age, sex, or genetic background; to the presence of the disease itself; or to adverse effects of glucocorticoid therapy. Cardiovascular disease, osteoporosis/fracture, metabolic and ocular comorbidity are of particular interest to clinicians because of their relationship to glucocorticoid therapy and the relevance to clinical treatment decisions regarding glucocorticoid tapering. Patients at high risk of exacerbation of comorbidity by glucocorticoid therapy may be considered for adjunctive steroid-sparing therapies and thus may need specialist management. From a public health perspective, with the ageing population the prevalence of PMR is predicted to increase; accurate data on comorbidity will be needed for planning and delivery of healthcare services.

show abstract

Section: Glucocorticoid-related Adverse Events In Polymyalgia Rheumaticamentioning

confidence: 99%

Comorbidity in polymyalgia rheumatica

Chatzigeorgiou

McDermott

2018

Reumatismo

View full text Add to dashboard Cite

show abstract

Prednisolone

2018

Reactions Weekly

View full text Add to dashboard Cite

Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases

Uribe-Reina¹,

Muñoz-Ortíz²,

Cifuentes-González³

et al. 2021

OPTH

View full text Add to dashboard Cite

Purpose To establish the prevalence of ocular involvement in a Colombian population with rheumatologic diseases. Design Observational cross-sectional study. Methods We included a probabilistic sample size of 797 patients who attended a rheumatologic disease center in Bogotá, Colombia. Statistical analysis with descriptive measures and Chi-square independence test between rheumatologic diseases and ophthalmological symptoms and diseases was performed. Results Eighty-four percent of the population were women, and the mean age was 54.61± 15.64 years. The most common condition was rheumatoid arthritis (33.37%), followed by fibromyalgia (22.71%), Sjögren Syndrome (19.72%), and systemic lupus erythematosus (9.91%). Almost 7% of the patients presented polyautoimmunity. Thirty-five percent of the patients reported one or more ophthalmological symptoms, being dry eye sensation the most common (30.86%), followed by ocular pain (2.76%), red-eye, and decreased visual acuity (both 2.63%). Similarly, 21.45% of the patients presented one or more ophthalmological diagnoses, being keratoconjunctivitis sicca the most common (15.93%), followed by cataract, uveitis (1.38% each), and scleritis (1.25%). Conclusion Almost a third of the patients reported any ocular involvement. It is crucial to be aware of the most common ophthalmic manifestations among the different rheumatologic diseases in our population, to offer early specialist referral and timely treatment.

show abstract

Ocular Inflammation Associated with Polymyalgia Rheumatica without Concomitant Giant-Cell Arteritis: A Report of Three Cases

Cited by 4 publications

References 5 publications

Comorbidity in polymyalgia rheumatica

Comorbidity in polymyalgia rheumatica

Prednisolone

Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases

Contact Info

Product

Resources

About